Q2 FY2026 EarningsQ2 FY26 results beat consensus across all major financial metrics, driven by accelerated PEDMARK product sales and the inclusion of Norgine licensing revenue. Revenue reached $17.87M vs. $16.12M expected (+10.87%), while Diluted EPS (GAAP) of $0.05 significantly outperformed the $0.02 mean estimate. The company achieved a successful pivot to profitability, supported by a managed cost structure and the settlement of patent litigation, reinforcing a positive outlook for AI-driven clinical expansion.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Fennec Pharma(FENC) the Revenue is 17.87 M (+85.18%), Beat estimate;the EBIT is 1.737 M (+163.6%), Beat estimate;the EPS is 0.05 (+145.5%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B85.18%
0.02B66.99%
+0.00B18.19%
EBITExceed expectations
0.00B163.58%
0.00B125.45%
+0.00B38.13%
EPSExceed expectations
0.05145.45%
0.02118.18%
+0.030027.27%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf